STAAR SURGICAL CO
No SEC Form 4 filings for $STAA in the last 30 days.
See all $STAA insider activity →STAAR Surgical (STAA) shares fell about 0.3% to around $25 after Q2 results. The quarter returned to profit, with net income of $8.1m and basic EPS of $0.16, on sales of $93.5m. China net sales were $52.3m. The company reported $181.5m cash and no debt, with gross margin at 74.5%.
Jefferies cut its price target for STAAR Surgical (STAA) to $28 from $29 but kept a Hold rating after the company’s Q2 2026 results. Revenue was $93.5M, flat QoQ and 4% above consensus. China sales were $52.3M. Gross margin was 74.5%, but EPS was $0.16 vs $0.22 consensus.
STAAR Surgical (STAA) reported Q2 2026 net sales of $93.5 million, up 111% year over year, driven by China. China sales were $52.3 million. Gross margin rose to 74.5%. Operating income was $10.1 million versus a $30.0 million loss a year earlier. Net income was $8.1 million ($0.16/share).
Over the past 7 days, alphai's AI scored 8 news stories mentioning STAA (STAAR SURGICAL CO). Coverage has skewed bullish: 4 bullish, 4 neutral, and 0 bearish.
Recent STAA coverage spans earnings, financial news and corporate actions.
Earnings show a sharp swing back to profitability, but the article emphasizes China concentration and tariff-driven margin drag, leaving durability uncertain.
Analyst PT reduction after an earnings setup where revenue beat but EPS missed, with no formal company guidance.
China-led demand drove a sharp profitability rebound, with management also flagging easing tariff pressure after Switzerland production shifts.
China-driven normalization plus improving profitability (operating income $10.1M vs loss) is a near-term positive read-through for STAA’s revenue durability and margin trajectory.
Beat on revenue and EPS improved margins this quarter, but the stock drop suggests investors focused on longer-term growth and profitability trends.
alphai scores every news story that mentions STAA with an AI model for sentiment and relevance, and aggregates insider trades from STAAR SURGICAL CO's SEC EDGAR Form 4 filings. Figures refresh continuously.
STAAR Surgical (STAA) shares fell about 0.3% to around $25 after Q2 results. The quarter returned to profit, with net income of $8.1m and basic EPS of $0.16, on sales of $93.5m. China net sales were $52.3m. The company reported $181.5m cash and no debt, with gross margin at 74.5%.
6 min readJefferies cut its price target for STAAR Surgical (STAA) to $28 from $29 but kept a Hold rating after the company’s Q2 2026 results. Revenue was $93.5M, flat QoQ and 4% above consensus. China sales were $52.3M. Gross margin was 74.5%, but EPS was $0.16 vs $0.22 consensus.
3 min readSTAAR Surgical (STAA) reported Q2 2026 net sales of $93.5 million, up 111% year over year, driven by China. China sales were $52.3 million. Gross margin rose to 74.5%. Operating income was $10.1 million versus a $30.0 million loss a year earlier. Net income was $8.1 million ($0.16/share).
4 min readSTAAR Surgical reported Q2 2026 net sales of $93.5 million, up 111% year over year. China generated $52.3 million, over half of revenue. Excluding China, sales rose 6%. Gross margin rose to 74.5% and operating income was $10.1 million. Net income was $8.1 million, or $0.16 diluted EPS.
4 min readSTAAR Surgical (NASDAQ:STAA) reported Q2 CY2026 revenue of $93.54 million, up 111% year on year and 3.3% above Wall Street estimates, according to the company. GAAP EPS was $0.16, up from -$0.34 a year earlier, and above consensus. The stock fell 8% to $23.38 after results. Analysts expect revenue to rise 2.7% over 12 months.
5 min readSTAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 staa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 STAAR Surgical Reports Second Quarter 2026 Results Net Sales of $93.5 million, up 111% Y/Y Net Income of $8.1 million, with GAAP EPS of $0.16 Adjusted EBITDA 1 of $20.0 million, or $0.39 per diluted share Earnings Call and We
6 min readSTAAR Surgical (NASDAQ: STAA) is set to report Q2 earnings Wednesday after market close. The company’s prior quarter revenue was $93.52 million, up 120% year over year. For the upcoming quarter, analysts expect revenue to rise 104% year over year. The article cites an average analyst price target of $28.70 versus a $25.31 share price.
4 min readMasimo and Staar Surgical appointed new executives amid prior deal and proxy turmoil. Masimo named Tim Benner president under Danaher ownership, succeeding Katie Szyman after Masimo’s $9.9B Danaher acquisition. Staar made Warren Foust permanent CEO after a failed $1.6B Alcon sale. Staar Q1 revenue rose to $93.5M; Q2 revenue expected over $90M.
4 min readSTAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.4 5 staa-ex10_4.htm EX-10.4 EX-10.4 Exhibit 10.4 STAAR SURGICAL COMPANY AMENDED AND RESTATED OMNIBUS EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE STAAR Surgical Company, a Delaware corporation, (the “ Company ”), pursuant to its Amended and Restated Omnibus Equity Incent
2 min readStaar Surgical appointed Warren Foust as permanent CEO and president. He has been interim co-CEO with Deborah Andrews since February after CEO Stephen Farrell left when Staar’s proposed $1.6 billion sale to Alcon fell through. Andrews will become executive vice president and keep CFO duties. Staar shares fell 3.2% to $23.34.
2 min read
